Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis

Mesalamine (5-ASA) is the mainstay therapy in patients with mild-to-moderate active ulcerative colitis (UC). However, non-adherence to therapy and practice variability among gastroenterologists represent long-standing barriers, leading to poor outcomes. Additionally, targets to treat in UC are incre...

Descripción completa

Detalles Bibliográficos
Autores principales: Solitano, Virginia, D’Amico, Ferdinando, Fiorino, Gionata, Paridaens, Kristine, Peyrin-Biroulet, Laurent, Danese, Silvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564568/
https://www.ncbi.nlm.nih.gov/pubmed/32911840
http://dx.doi.org/10.3390/jcm9092905

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564568/
https://www.ncbi.nlm.nih.gov/pubmed/32911840
http://dx.doi.org/10.3390/jcm9092905

Ejemplares similares